Lan Xie - SciClone Pharmaceuticals VP of Fin. and CFO of China Operations

CFO

Ms. Lan Xie, CPA, is Vice President Finance, China Chief Financial Officer of SciClone Pharmaceuticals, Inc. Ms. Xie joined SciClone as Vice President Finance, China Chief Financial Officer in August 2012. From 2007 to 2012, Ms. Xie served as Vice President of Finance and Investor Relations at ShangPharma Corporationrationration, a pharmaceutical company. From 2005 to 2007, Ms. Xie served as a senior manager, transaction services, at PricewaterhouseCoopers Zhong Tian LLP in Shanghai and from 2003 to 2005, Ms. Xie served as manager, mergers and acquisitions at Deloitte Touche in New York since 2012.
Age 41
Tenure 12 years
Professional MarksMBA
Phone650 358-3456
Webwww.sciclone.com
Xie also served in various finance and accounting positions at Reuters Incorporated and PricewaterhouseCoopers in Boston. She is a Massachusetts certified public accountant and received her M.B.A from INSEAD, Singapore/France.

SciClone Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of 0.16 % which means that it generated a profit of $0.16 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.19 %, meaning that it created $0.19 on every $100 dollars invested by stockholders. SciClone Pharmaceuticals' management efficiency ratios could be used to measure how well SciClone Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 2.73 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. SciClone Pharmaceuticals has a current ratio of 8.19, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist SciClone Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, SciClone Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like SciClone Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for SciClone to invest in growth at high rates of return. When we think about SciClone Pharmaceuticals' use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 5 records

CFO Age

Scott BehrensAlbertsons Companies
44
Tracy TanPrimerica
53
John DrexlerAlbertsons Companies
45
Gary EsqHanover Foods
58
Michael CPACincinnati Financial
60
SciClone Pharmaceuticals, Inc., a specialty pharmaceutical company, offer therapies for oncology, infectious diseases, and cardiovascular disorders in the People?s Republic of China, the United States, and Hong Kong. SciClone Pharmaceuticals (SCLN) is traded on NASDAQ Exchange in USA and employs 590 people.

Management Performance

SciClone Pharmaceuticals Leadership Team

Elected by the shareholders, the SciClone Pharmaceuticals' board of directors comprises two types of representatives: SciClone Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of SciClone. The board's role is to monitor SciClone Pharmaceuticals' management team and ensure that shareholders' interests are well served. SciClone Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, SciClone Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Charles Meng, VP of Compliance and General Counsel
Richard Hawkins, Independent Director
Gregg Lapointe, Independent Director
Hong Zhao, CEO of China Operations
Wilson Cheung, CFO, Sr. VP of Fin. and Secretary
Nancy Chang, Director
Anthony Lapointe, Independent Director
Lan Xie, VP of Fin. and CFO of China Operations
Raymond Low, Vice President - Finance, Controller
Robert King, Senior Vice President - Product Development and Supply Chain
Simon Li, Independent Director
Jon Saxe, Independent Chairman of the Board
Friedhelm Blobel, CEO and President Executive Director and Member of Bus. Devel. Committee

SciClone Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is SciClone Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Other Consideration for investing in SciClone Stock

If you are still planning to invest in SciClone Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the SciClone Pharmaceuticals' history and understand the potential risks before investing.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Fundamental Analysis
View fundamental data based on most recent published financial statements
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios